Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: A substudy of the WANECAM randomised trial

The Lancet Infectious Diseases

Volumn 16, Issue 2, 2016, Pages 189-198

  Sagara, Issaka ^a   Beavogui, Abdoul Habib ^b   Zongo, Issaka ^c   Soulama, Issiaka ^d   Borghini Fuhrer, Isabelle ^e   Fofana, Bakary ^a   Camara, Daouda ^b   Somé, Anyirékun F ^c   Coulibaly, Aboubacar S ^d   Traore, Oumar B ^a   Dara, Niawanlou ^a   Kabore, Moïse J T ^d   Thera, Ismaila ^a   Compaore, Yves D ^c   Sylla, Malick Minkael ^b   Nikiema, Frederic ^c   Diallo, Mamadou Saliou ^b   Dicko, Alassane ^a   Gil, Jose Pedro ^f   Borrmann, Steffen ^g,h   Duparc, Stephan ^e   Miller, Robert M ^i,l   Doumbo, Ogobara K ^a   Shin, Jangsik ^j   Bjorkman, Anders ^k   Ouedraogo, Jean Bosco ^c   Sirima, Sodiomon B ^d   Djimdé, Abdoulaye A ^a   more..

^a Sociétés   (Mali)

^b Centre de Formation et de Recherche en Santé Rurale de Maferinyah   (Guinea)

^c Institut de Recherche en Sciences de la Sante   (Burkina Faso)

^d Burkina Faso   (Burkina Faso)

^e Medicines for Malaria Venture   (Switzerland)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h German Center for Research in Infectious Disease (DZIF)   (Germany)

ⁱ ICON PLC   (United Kingdom)

^j Shin Poong Pharmaceutical Company   (South Korea)

^k KAROLINSKA INSTITUTE   (Sweden)

^l Artemida Pharma   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ARTESUNATE PLUS PYRONARIDINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; DRUG COMBINATION; NAPHTHYRIDINE DERIVATIVE; PYRONARIDINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AFRICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CHILD; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; FEVER; HEALTH CARE FACILITY; HUMAN; HYPERBILIRUBINEMIA; LABORATORY TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALARIA; MALE; MEDICAL HISTORY; MONOCYTOSIS; NEUTROPENIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PLASMODIUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; SIDE EFFECT; THROMBOCYTOPENIA; TOXIC HEPATITIS; WEST AFRICAN; AGED; BURKINA FASO; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; GUINEA; INFANT; MALI; MIDDLE AGED; PRESCHOOL CHILD; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; ARTEMISININS; BURKINA FASO; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; GUINEA; HUMANS; INFANT; MALARIA; MALE; MALI; MIDDLE AGED; NAPHTHYRIDINES; PLASMODIUM; RETREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84957432274     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00318-7     Document Type: Article

References (19)

1. Croft SL, Duparc S, Arbe-Barnes SJ, et al. Review of pyronaridine anti-malarial properties and product characteristics. Malar J 2012, 11:270.
2. Summary of opinion: Pyramax (pyronaridine tetraphosphate/artesunate) Committee for Medicinal Products for Human Use (CHMP), (accessed Sept 8, 2014). http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/02/WC500122945.pdf.
3. Kayentao K, Doumbo OK, Penali LK, et al. Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malar J 2012, 11:364.
4. Poravuth Y, Socheat D, Rueangweerayut R, et al. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One 2011, 6:e14501.
5. Rueangweerayut R, Phyo AP, Uthaisin C, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med 2012, 366:1298-1309.
6. Tshefu AK, Gaye O, Kayentao K, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 2010, 375:1457-1467. the Pyronaridine-artesunate Study Team.
7. Duparc S, Borghini-Fuhrer I, Craft CJ, et al. Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. Malar J 2013, 12:70.
8. Ramharter M, Kurth F, Schreier AC, et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis 2008, 198:911-919.
9. Guidance for Industry. Drug-induced Liver Injury: premarketing Clinical Evaluation US Department of Health and Human Services, Food and Drug AdministrationFood and Drug Administration, Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Center for biologics Evaluation and Research (CBER)Center for biologics Evaluation and Research (CBER), (accessed April 5, 2014). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/Guidances/UCM174090.pdf.
10. Yeka A, Lameyre V, Afizi K, et al. Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children. PLoS One 2014, 9:e113311.
11. Sagara I, Fofana B, Gaudart J, et al. Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact. Am J Trop Med Hyg 2012, 87:50-56.
12. Ndiaye JL, Faye B, Gueye A, et al. Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. Malar J 2011, 10:237.
13. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria World Health Organization, (accessed March 10, 2014). http://www.who.int/malaria/publications/atoz/whohtmrbm200350/en/.
14. Ranford-Cartwright LC, Taylor J, Umasunthar T, et al. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg 1997, 91:719-724.
15. Sagara I, Dicko A, Djimde A, et al. A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg 2006, 75:630-636.
16. Snounou G, Viriyakosol S, Zhu XP, et al. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. Mol Biochem Parasitol 1993, 61:315-320.
17. Djimde A, Lefevre G Understanding the pharmacokinetics of Coartem. Malar J 2009, 8(suppl 1):S4.
18. Methods of surveillance of antimalarial drug efficacy World Health Organization, (accessed April 24, 2015). http://www.who.int/malaria/publications/atoz/9789241597531/en/.
19. Premji ZG, Abdulla S, Ogutu B, et al. The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence. Malar J 2008, 7:244.